Prevention of arginine-vasopressin-induced motor disturbances by a potent vasopressor antagonist.
The antivasopressor analog d(CH2)5Tyr(Me) arginine-vasopressin completely blocked the convulsive-like behavior and other severe motor disturbances which are normally observed following a second central arginine-vasopressin injection. This vasopressor antagonist appears to be selective for arginine-vasopressin-induced motor disturbances, in that the convulsive and motor effects of pentylenetetrazol and somatostatin were not altered significantly by pretreatment with the central antagonist. Results suggest that arginine-vasopressin-induced motor disturbances are mediated via central receptors. The classic antidiuretic (V2) type of arginine-vasopressin receptor does not appear to be involved, since the agonist 1-desamino-8-D-arginine-vasopressin did not elicit convulsive-like behavior or other severe motor disturbances 2 days following a first ('priming') injection of arginine-vasopressin.
Burnard
D M
DM
Veale
W L
WL
Pittman
Q J
QJ
D000818:Animals; D001127:Arginine Vasopressin / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use; D001927:Brain Diseases / Q000517:prevention & control; D003894:Deamino Arginine Vasopressin / Q000494:pharmacology; D004342:Drug Hypersensitivity / Q000517:prevention & control; D008297:Male; D009069:Movement Disorders / Q000139:chemically induced / Q000517:prevention & control*; D010433:Pentylenetetrazole / Q000494:pharmacology; D051381:Rats; D011919:Rats, Inbred Strains; D013004:Somatostatin / Q000494:pharmacology; D014662:Vasoconstrictor Agents / Q000037:antagonists & inhibitors*
D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin; D013004:Somatostatin; C025043:vasopressin, 1-(1-mercaptocyclohexaneacetic acid)-2-(O- methyl-L-tyrosine)-8-L-arginine-; D003894:Deamino Arginine Vasopressin; D010433:Pentylenetetrazole